“As clinicians, it’s important to recognize this and help patients adapt as well as possible.”
You Might Also Like
Also By This Author
Thomas R. Collins is a freelance medical writer based in Florida.
ad goes here:advert-1
SCROLL TO CONTINUE
- Gianfrancesco MA, Leykina LA, Izadi Z, et al. Race/ethnicity association with COVID-19 outcomes in rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance Physician Registry. Arthritis Rheumatol. 2020 Nov 3. Online ahead of print.
- Gianfrancesco MA, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 Jul;79(7):859–866.
- Kilian, A, Chock YP, Huang IJ, et al. Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. Semin Arthritis Rheum. 2020 Oct;50(5):1191–1201.
- Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids , but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: Results from an international registry. Gastroenterology. 2020 Aug;159(2):481–491.
- Eli Lilly & Company. News release: Baricitinib in combination with remdesivir reduces time to recovery in hospitalized patients with COVID-19 in NIAID-sponsored ACTT-2 trial. 2020 Sep 14.